|
Chronic sinusitis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Chronic otitis media
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Recurrent bronchitis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Patients in need of TPN, burns, trauma or malignancies should continue to benefit from supplemental GLN, administered either intravenously at less than 0.35 g/kg/day or enterally at less than 0.5 g/kg/day.
|
31247630 |
2019 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
To deliver personalized RNA-based-therapy targeting oncogenic miRNAs that form part of this common PDAC miRNA over-expression signature, we packaged antimiR oligonucleotides against one of these miRNAs in tumor-penetrating nanocomplexes (TPN) targeting cell surface proteins on PDAC tumors.<b>Results:</b> As a validation for our pre-clinical strategy, the therapeutic potential of one of our nano-drugs, TPN-21, was first shown to decrease tumor cell growth and survival in PDO avatars for individual patients, then in their PDX avatars.<b>Conclusions:</b> This general approach appears suitable for co-clinical validation of personalized RNA medicine and paves the way to prospectively identify patients with eligible miRNA profiles for personalized RNA-based therapy.<i>Clin Cancer Res; 24(7); 1734-47.©2018 AACR</i>.
|
29330203 |
2018 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Notably, migration of cancer cell was significantly inhibited when treated with FIS-TPN formulations.
|
28004315 |
2017 |
|
Hepatitis C
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Our study implicated that TAP2, HLA-DOA, HLA-DOB, and tapasin loci were novel candidate regions for susceptibility to HCV infection and viral clearance in the Chinese population.
|
25874709 |
2015 |
|
Hepatitis C
|
0.030 |
Biomarker
|
disease |
BEFREE |
The current study determined the genotypes of 34 tagging-SNPs (single nucleotide polymorphisms) from 9 candidate genes (HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, TAP1, TAP2, LMP2, LMP7, and tapasin) in a Chinese population of paid blood donors with high risk of HCV infection.
|
25528575 |
2014 |
|
Hepatitis C
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Tapasin alleles contribute to the outcome of HCV infection by synergizing with polymorphisms at HLA-B in a population-specific manner.
|
23532923 |
2013 |
|
Diabetes
|
0.020 |
Biomarker
|
disease |
BEFREE |
To compare the effectiveness (metabolic control) and safety of two insulin regimens in patients with diabetes receiving TPN.
|
30930133 |
2020 |
|
Diabetes Mellitus
|
0.020 |
Biomarker
|
group |
BEFREE |
To compare the effectiveness (metabolic control) and safety of two insulin regimens in patients with diabetes receiving TPN.
|
30930133 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.020 |
Biomarker
|
disease |
BEFREE |
Prospective, open-label, multicenter, clinical trial on adult inpatients with type 2 diabetes on a non-critical setting with indication for TPN.
|
30930133 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
BG = blood glucose; CG = conventional glycemic control; ENT = enteral nutrition therapy; GIP = glucose-dependent insulinotropic polypeptide; GLP-1 = glucagon-like peptide 1; IG = intensive glycemic control; IV = intravenous; NPH = neutral protamine Hagedorn; PNT = parenteral nutrition therapy; SQ = subcutaneous; T2DM = type 2 diabetes mellitus; TDD = total daily dose; TPN = total parenteral nutrition.
|
30035626 |
2018 |
|
Ankylosing spondylitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
In this study, we conducted classical molecular dynamics simulations of two HLA alleles, the ankylosing spondylitis (AS) associated/tapasin-dependent HLA-B*27:05 and nondisease-associated/tapasin-independent HLA-B*27:09, both in peptide-free forms as well as complex with four different peptides ligands.
|
28278760 |
2018 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
To deliver personalized RNA-based-therapy targeting oncogenic miRNAs that form part of this common PDAC miRNA over-expression signature, we packaged antimiR oligonucleotides against one of these miRNAs in tumor-penetrating nanocomplexes (TPN) targeting cell surface proteins on PDAC tumors.<b>Results:</b> As a validation for our pre-clinical strategy, the therapeutic potential of one of our nano-drugs, TPN-21, was first shown to decrease tumor cell growth and survival in PDO avatars for individual patients, then in their PDX avatars.<b>Conclusions:</b> This general approach appears suitable for co-clinical validation of personalized RNA medicine and paves the way to prospectively identify patients with eligible miRNA profiles for personalized RNA-based therapy.<i>Clin Cancer Res; 24(7); 1734-47.©2018 AACR</i>.
|
29330203 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we assessed tapasin expression in 85 primary tumor lesions of non-small cell lung cancer (NSCLC) patients, demonstrating that tapasin expression positively correlated with patient survival.
|
28344889 |
2017 |
|
Diabetes
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The following characteristics were significantly associated with severe CKD: female gender (HR 1.34), older age (HR 1.38/10 year increment), catheter-related sepsis (HR 1.58), steroid maintenance immunosuppression (HR 1.50), graft failure (HR 1.76), ACR (HR 1.64), prolonged requirement for IV fluids (HR 2.12) or TPN (HR 1.94), and diabetes (HR 1.54).
|
28241392 |
2017 |
|
Diabetes Mellitus
|
0.020 |
GeneticVariation
|
group |
BEFREE |
The following characteristics were significantly associated with severe CKD: female gender (HR 1.34), older age (HR 1.38/10 year increment), catheter-related sepsis (HR 1.58), steroid maintenance immunosuppression (HR 1.50), graft failure (HR 1.76), ACR (HR 1.64), prolonged requirement for IV fluids (HR 2.12) or TPN (HR 1.94), and diabetes (HR 1.54).
|
28241392 |
2017 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Notably, migration of cancer cell was significantly inhibited when treated with FIS-TPN formulations.
|
28004315 |
2017 |
|
Colorectal Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Consistent with published functional data showing that tapasin promotes antigen presentation, as well as tumor immune recognition and destruction by CD8(+) CTLs, a reduction in tapasin expression is associated with tumor progression in CRC.
|
26310568 |
2015 |
|
Neoplasm Metastasis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
A reduction of tapasin expression strongly correlated with venous invasion (AUC 0.682, OR 2.7, p = 0.002; 95% CI 1.7-5.0), lymphatic invasion (AUC 0.620, OR 2.0, p = 0.005; 95 % CI 1.3-3.3), distant metastasis (AUC 0.727, OR 2.9, p = 0.004; 95% CI 1.4-5.9) and an infiltrative tumor border configuration (AUC 0.621, OR 2.2, p = 0.017; 95% CI 1.2-4.4).
|
26310568 |
2015 |
|
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
A reduction of tapasin expression strongly correlated with venous invasion (AUC 0.682, OR 2.7, p = 0.002; 95% CI 1.7-5.0), lymphatic invasion (AUC 0.620, OR 2.0, p = 0.005; 95 % CI 1.3-3.3), distant metastasis (AUC 0.727, OR 2.9, p = 0.004; 95% CI 1.4-5.9) and an infiltrative tumor border configuration (AUC 0.621, OR 2.2, p = 0.017; 95% CI 1.2-4.4).
|
26310568 |
2015 |
|
Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Tapasin and human leukocyte antigen class I dysregulation correlates with survival in glioblastoma multiforme.
|
25175688 |
2014 |
|
Colorectal Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Finally, we determined that rs3106189, localized to the 5' UTR of antigen presenting tapasin binding protein (TAPBP), and rs1052918, localized to the 3' UTR of transcription factor 3 (TCF3), were associated with overall survival of CRC patients.
|
23940558 |
2013 |
|
Tumor Cell Invasion
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
TAP1, CNX, LMP7, Erp57 and Tapasin loss were significantly associated with tumor grading, lymph node metastasis and depth of invasion (P < 0.05).
|
21362330 |
2011 |